Patents by Inventor Mary Jane Cardosa

Mary Jane Cardosa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11154614
    Abstract: The present invention relates to the production of structural proteins and virus-like particles (VLPs) of flaviviruses and hepatitis C. Production is through use of a single expression cassette comprising a viral structural gene, a furin encoding gene and a bicistronic expression element such as an internal ribosome entry site (IRES) between the viral and furin genes. Both the viral gene and furin gene can include a partial capsid encoding sequence acting as a signal peptide to co-locate the viral protein and furin and to act as a membrane anchor for the viral protein and furin. A separate expression cassette comprising a non-structural viral gene can be combined with the initial cassette. The structural proteins and VLPs can be used in vaccines and in the treatment of viral infections.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: October 26, 2021
    Assignee: INTEGRATED RESEARCH ASSOCIATES, LLC
    Inventors: Mary Jane Cardosa, Katharine Bossart
  • Patent number: 10822397
    Abstract: This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of Human Enterovirus 71 (EV71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of Human Enterovirus 71 (EV71).
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: November 3, 2020
    Assignee: MAB Explorations Sdn Bhd
    Inventor: Mary Jane Cardosa
  • Patent number: 10555997
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 11, 2020
    Assignee: SENTINEXT THERAPEUTICS Sdn Bhd
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Patent number: 10548964
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 4, 2020
    Assignee: SENTINEXT THERAPEUTICS Sdn Bhd
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Publication number: 20190247488
    Abstract: This invention relates to Virus-Like Particles (VLPs) derived from Enterovirus and vaccines comprising such VLPs which elicit immune responses and/or protective neutralizing antibody responses directed against an Enterovirus. The instant invention provides expression cassettes and methods for making Enterovirus CV-A16 VLPs and compositions enriched in CV-A16 VLPs which exhibit conformational epitopes which elicit immune responses and/or neutralizing antibody responses which may be used in vaccines directed against Enterovirus CV-A16.
    Type: Application
    Filed: September 21, 2017
    Publication date: August 15, 2019
    Inventor: Mary Jane CARDOSA
  • Publication number: 20190224304
    Abstract: The invention provides chimeric Enterovirus virus-like particles (VLPs) for protection and/or treatment against infection by more than one Enterovirus. More specifically, the present invention provides chimeric EV-A71 virus-like particles displaying CV-A16 VP1 polypeptides and at the same time maintaining important neutralizing antibody epitopes of EV-A71 itself. More specifically, the present invention provides chimeric CV-A16 virus-like particles displaying EV-A71 VP1 polypeptides. Thus, the present invention provides a bivalent vaccine comprising the chimeric virus-like particles which elicit an immune response and/or neutralizing antibody response to both EV-A71 and CVA-16 for the treatment of Hand, Foot and Mouth Disease.
    Type: Application
    Filed: September 21, 2017
    Publication date: July 25, 2019
    Inventor: Mary Jane CARDOSA
  • Publication number: 20190125862
    Abstract: The present invention relates to the production of structural proteins and virus-like particles (VLPs) of flaviviruses and hepatitis C. Production is through use of a single expression cassette comprising a viral structural gene, a furin encoding gene and a bicistronic expression element such as an internal ribosome entry site (IRES) between the viral and furin genes. Both the viral gene and furin gene can include a partial capsid encoding sequence acting as a signal peptide to co-locate the viral protein and furin and to act as a membrane anchor for the viral protein and furin. A separate expression cassette comprising a non-structural viral gene can be combined with the initial cassette. The structural proteins and VLPs can be used in vaccines and in the treatment of viral infections.
    Type: Application
    Filed: April 19, 2017
    Publication date: May 2, 2019
    Inventors: Mary Jane CARDOSA, Katharine BOSSART
  • Publication number: 20190100574
    Abstract: This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of Human Enterovirus 71 (EV71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of Human Enterovirus 71 (EV71).
    Type: Application
    Filed: October 10, 2018
    Publication date: April 4, 2019
    Inventor: Mary Jane Cardosa
  • Patent number: 10125187
    Abstract: This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of enterovirus 71 (EV71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of enterovirus 71 (EV71).
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: November 13, 2018
    Assignee: MAB Explorations Sdn Bhd
    Inventor: Mary Jane Cardosa
  • Publication number: 20180271971
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 27, 2018
    Inventors: Mary Jane CARDOSA, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Publication number: 20180243400
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Inventors: Mary Jane CARDOSA, Mohamad Fakruddin JAMILUDDIN, Sharifah Binti HAMID
  • Patent number: 9987350
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human Enterovirus B, Human enterovirus C, Human Enterovirus D antigens and their use in vaccines for the prevention of an enterovirus infection.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: June 5, 2018
    Assignee: SENTINEXT THERAPEUTICS Sdn Bhd
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Publication number: 20160333075
    Abstract: This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of enterovirus 71 (EV71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of enterovirus 71 (EV71).
    Type: Application
    Filed: December 16, 2014
    Publication date: November 17, 2016
    Inventor: Mary Jane Cardosa
  • Publication number: 20150140027
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 21, 2015
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Publication number: 20150056244
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 26, 2015
    Applicant: SENTINEXT THERAPEUTICS SDN BHD
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Patent number: 8815501
    Abstract: The present invention relates to NS1 proteins or parts thereof of Flaviviruses, in particular of Dengue viruses useful for vaccination against said Flavivirus and against one or more other Flaviviruses. The invention further concerns the NS1 protein or parts thereof of one Dengue virus serotype, in particular serotype 2, useful for vaccination against Dengue viruses from all serotypes. The invention further concerns DNA comprising an expression cassette coding for a Flavivirus NS1 or parts thereof, vectors comprising said DNA and vaccines containing or expressing a Flavivirus NS1.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: August 26, 2014
    Assignees: Bavarian Nordic A/S, Venture Technologies SDN BHD
    Inventors: Paul Howley, Sonja Leyrer, Mary Jane Cardosa, Magdeline Sia Henry Sum
  • Patent number: 7994288
    Abstract: This invention relates to allergenic proteins of natural rubber latex in substantially purified form, their production and their use, together with monoclonal antibodies developed against those allergenic proteins, in assays for the qualitative and quantitative determination of the levels of the allergenic proteins in natural rubber latex or in products made from latex. Assays for identifying and/or quantitating antibodies in blood or blood products that mediate the occurrence of an allergic reaction induced by natural rubber latex are also provided, together with in vivo and in vitro diagnostic tests for detecting hypersensitivity to natural rubber latex and which involve use of the aforesaid allergenic proteins. The invention also provides for the use of the aforesaid allergens as de-sensitising agents in the treatment of latex protein allergy. There is still further provided a method for removing allergenic proteins from latex products.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: August 9, 2011
    Assignees: The Board of the Rubber Research Institute of Malaysia, Universiti Sains Malaysia
    Inventors: Mary Jane Cardosa, Hamid Sharifah, Shirley Samuel-Verghese, Elumalai Sunderasan, Hoong Yeet Yeang, Hamzah Samsidar
  • Patent number: 7759116
    Abstract: The present invention relates to NS1 proteins or parts thereof of Flaviviruses, in particular of Dengue viruses useful for vaccination against said Flavivirus and against one or more other Flaviviruses. The invention further concerns the NS1 protein or parts thereof of one Dengue virus serotype, in particular serotype 2, useful for vaccination against Dengue viruses from all serotypes. The invention further concerns DNA comprising an expression cassette coding for a Flavivirus NS1 or parts thereof, vectors comprising said DNA and vaccines containing or expressing a Flavivirus NS1.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: July 20, 2010
    Assignees: Bavarian Nordic A/S, Venture Technologies SDN BHD
    Inventors: Paul Howley, Sonja Leyrer, Mary Jane Cardosa, Magdeline Sia Henry Sum
  • Publication number: 20100136054
    Abstract: The present invention relates to NS1 proteins or parts thereof of Flaviviruses, in particular of Dengue viruses useful for vaccination against said Flavivirus and against one or more other Flaviviruses. The invention further concerns the NS1 protein or parts thereof of one Dengue virus serotype, in particular serotype 2, useful for vaccination against Dengue viruses from all serotypes. The invention further concerns DNA comprising an expression cassette coding for a Flavivirus NS1 or parts thereof, vectors comprising said DNA and vaccines containing or expressing a Flavivirus NS1.
    Type: Application
    Filed: June 19, 2009
    Publication date: June 3, 2010
    Inventors: Paul Howley, Sonja Leyrer, Mary Jane Cardosa, Magdeline Sia Henry Sum
  • Publication number: 20100047280
    Abstract: The present invention relates to NS1 proteins or parts thereof of Flaviviruses, in particular of Dengue viruses useful for vaccination against said Flavivirus and against one or more other Flaviviruses. The invention further concerns the NS1 protein or parts thereof of one Dengue virus serotype, in particular serotype 2, useful for vaccination against Dengue viruses from all serotypes. The invention further concerns DNA comprising an expression cassette coding for a Flavivirus NS1 or parts thereof, vectors comprising said DNA and vaccines containing or expressing a Flavivirus NS1.
    Type: Application
    Filed: February 27, 2008
    Publication date: February 25, 2010
    Inventors: Paul Howley, Sonja Leyrer, Mary Jane Cardosa, Magdeline Sia Henry Sum